Relationship between endothelial dysfunction and nocturia with benign prostatic hyperplasia

References

• Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361:1359–67.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging 2011;6:161–72.
   PubMed Web of Science ®Google Scholar
• Hilton P, Stanton SL. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br J Urol 1982;54:252–5.
   PubMedGoogle Scholar
• Agarwal R, Light RP, Bills JE, Hummel LA. Nocturia, nocturnal activity, and nondipping. Hypertension 2009;54:646–51.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Jeong SJ, Byun SS, Lee JJ, Han JW, Kim KW. Prevalence and correlates of nocturia in community-dwelling older men: results from the Korean longitudinal study on health and aging. Korean J Urol 2012;53:263–7.
   PubMedGoogle Scholar
• Fiske J, Scarpero HM, Xue X, Nitti VW. Degree of bother caused by nocturia in women. Neurourol Urodyn 2004;23:130–3.
   PubMed Web of Science ®Google Scholar
• Yu HJ, Chen FY, Huang PC, Chen TH, Chie WC, Liu CY. Impact of nocturia on symptom-specific quality of life among community-dwelling adults aged 40 years and older. Urology 2006;67:713–18.
   PubMed Web of Science ®Google Scholar
• Asplund R, Johansson S, Henriksson S, Isacsson G. Nocturia, depression and antidepressant medication. BJU Int 2005;95:820–3.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003;91:190–5.
   PubMed Web of Science ®Google Scholar
• Van Dijk L, Kooij DG, Schellevis FG. Nocturia in the Dutch adult population. BJU Int 2002;90:644–8.
   PubMed Web of Science ®Google Scholar
• Asplund R, Aberg H. Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 1992;10:98–104.
   PubMedGoogle Scholar
• Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992;40:1217–20.
   PubMed Web of Science ®Google Scholar
• Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999;84:297–301.
   PubMed Web of Science ®Google Scholar
• Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899–906.
   PubMed Web of Science ®Google Scholar
• Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998;82:1535–9; A1537–8.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34:62–9.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52.
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.
   PubMed Web of Science ®Google Scholar
• Turgut F, Bayrak O, Kanbay M, Ozkara A, Uz E, Bavbek N, et al. Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia. Scand J Urol Nephrol 2008;42:47–52.
   PubMed Web of Science ®Google Scholar
• Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004;38:405–16.
   PubMed Web of Science ®Google Scholar
• Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390–3.
   PubMed Web of Science ®Google Scholar
• Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther 1999;21:1732–48.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151–8.
   PubMed Web of Science ®Google Scholar
• Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G, et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003;57:57–65.
   PubMed Web of Science ®Google Scholar
• Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007;177:1395–400.
   PubMed Web of Science ®Google Scholar
• Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199–206.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006;68:1198–205.
   PubMed Web of Science ®Google Scholar
• Garbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol 2010;12:157–80.
   Google Scholar
• Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935–44.
   PubMed Web of Science ®Google Scholar
• Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006;98:1038–42.
   PubMed Web of Science ®Google Scholar
• Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725–9.
   PubMed Web of Science ®Google Scholar
• Ghafar MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002;3:292–6.
   PubMedGoogle Scholar